Lates News

Hansen Pharmaceuticals announced that the Group's independently developed new drug HS-20152 injection has obtained the drug clinical trial approval notification issued by the China National Medical Products Administration, and intends to conduct clinical trials for paroxysmal nocturnal hemoglobinuria.